The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer

Urol Clin North Am. 2020 Nov;47(4):457-467. doi: 10.1016/j.ucl.2020.07.004.


Biochemically recurrent prostate cancer represents a stage of prostate cancer where conventional (continued on next page) computed tomography and technetium Tc 99m bone scan imaging are unable to detect disease after curative intervention despite rising prostate-specific antigen. There is no clear standard of care and no systemic therapy has been shown to improve survival. Immunotherapy-based treatments potentially are attractive options relative to androgen deprivation therapy due to the generally more favorable side-effect profile. Biochemically recurrent prostate cancer patients have a low tumor burden and likely lymph node-based disease, which may make them more likely to respond to immunotherapy.

Keywords: Biochemically recurrent; Immunotherapy-based treatment; Prostate cancer; Systemic therapy.

Publication types

  • Review

MeSH terms

  • Aged
  • Androgen Antagonists / therapeutic use*
  • Combined Modality Therapy
  • Disease-Free Survival
  • Humans
  • Immunotherapy / methods*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / diagnostic imaging
  • Neoplasm Recurrence, Local / mortality
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Recurrence, Local / therapy*
  • Patient Selection
  • Prognosis
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / pathology*
  • Prostatic Neoplasms / therapy
  • Risk Assessment
  • Role
  • Survival Analysis
  • Tomography, X-Ray Computed / methods
  • Treatment Outcome


  • Androgen Antagonists
  • Prostate-Specific Antigen